Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies
| العنوان: | Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies |
|---|---|
| المؤلفون: | Thomas Appl, Christian Drosten, Patrick Wuchter, David Juhl, Michael Schmidt, Sixten Körper, Rainer Blasczyk, Bernd Jahrsdörfer, Hubert Schrezenmeier, Harald Klüter, Hermann Eichler, Erhard Seifried, Tatjana Schwarz, Victor M. Corman, Thomas Burkhardt, Richard Schäfer, Nina Gödecke, Jan Pilch, Torsten Tonn, Rebecca Müller, Tamam Bakchoul |
| المصدر: | Transfus Med Hemother |
| بيانات النشر: | S. Karger AG, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | biology, business.industry, medicine.medical_treatment, Antibody titer, Hematology, 030204 cardiovascular system & hematology, Neutralization, law.invention, 03 medical and health sciences, Titer, 0302 clinical medicine, Randomized controlled trial, law, ABO blood group system, Immunology, biology.protein, Immunology and Allergy, Medicine, Plasmapheresis, Antibody, business, Neutralizing antibody, Research Article, 030215 immunology |
| الوصف: | Background Convalescent plasma is one of the treatment options for COVID-19 which is currently being investigated in many clinical trials. Understanding of donor and product characteristics is important for optimization of convalescent plasma. Methods Patients who had recovered from COVID-19 were recruited as donors for COVID-19 convalescent plasma (CCP) for a randomized clinical trial of CCP for treatment of severe COVID-19 (CAPSID Trial). Titers of neutralizing antibodies were measured by a plaque-reduction neutralization test (PRNT). Correlation of antibody titers with host factors and evolution of neutralizing antibody titers over time in repeat donors were analysed. Results A series of 144 donors (41% females, 59% males; median age 40 years) underwent 319 plasmapheresis procedures providing a median collection volume of 850 mL and a mean number of 2.7 therapeutic units per plasmapheresis. The majority of donors had a mild or moderate course of COVID-19. The titers of neutralizing antibodies varied greatly between CCP donors (from 1:640). Donor factors (gender, age, ABO type, body weight) did not correlate significantly with the titer of neutralizing antibodies. We observed a significant positive correlation of neutralization titers with the number of reported COVID-19 symptoms and with the time from SARS-CoV-2 diagnosis to plasmapheresis. Neutralizing antibody levels were stable or increased over time in 58% of repeat CCP donors. Mean titers of neutralizing antibodies of first donation and last donation of repeat CCP donors did not differ significantly (1:86 at first compared to 1:87 at the last donation). There was a significant correlation of neutralizing antibodies measured by PRNT and anti-SARS-CoV-2 IgG and IgA antibodies which were measured by ELISA. CCP donations with an anti-SARS-CoV-2 IgG antibody content above the 25th percentile were substantially enriched for CCP donations with higher neutralizing antibody levels. Conclusion We demonstrate the feasibility of collection of a large number of CCP products under a harmonized protocol for a randomized clinical trial. Titers of neutralizing antibodies were stable or increased over time in a subgroup of repeat donors. A history of higher number of COVID-19 symptoms and higher levels of anti-SARS-CoV-2 IgG and IgA antibodies in immunoassays can preselect donations with higher neutralizing capacity. |
| تدمد: | 1660-3818 1660-3796 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7f3f05e7c7bfa45dd4a51bfac69a75dTest https://doi.org/10.1159/000515610Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....d7f3f05e7c7bfa45dd4a51bfac69a75d |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16603818 16603796 |
|---|